Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Adult HBV Vaccination: Current Vaccines and Vaccination Strategies

Listen to expert discussion of current HBV vaccine formulations and applying up-to-date recommendations for routine vaccination, including in special situations.
Robert G. Gish, MD
Released: May 5, 2022

In this episode, listen as Robert G. Gish, MD, discusses key information on comparing current HBV vaccine formulations, and learn the best immunization practices for routine vaccination, including in special situations.

Information on this Educational Activity


Robert G. Gish, MD

Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
Clinical Professor
University of Nevada Reno School of Medicine
Clinical Professor
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director

Hepatitis B Foundation
Washington, DC

Robert G. Gish, MD, has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Fibronostics, Fujifilm/Wako, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, Hepatx, HepQuant, Intercept, Janssen, Merck, Perspectum, Pfizer, Quest, Sonic Incytes, and Topography Health, and Venatorx; has served on advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer and Prodigy; serves on current clinical trials alliance for Topography Health; and has served on data and safety monitoring boards for Altimmune, Arrowhead, CymaBay, and Durect; serves on speakers bureaus for AbbVie, BMS, Eisai, Genentech, Gilead Sciences, and Intercept; and has stock options with Eiger, Genlantis, HepQuant, AngioCrine, HepaTx.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
VBI Vaccines Inc.

Related Content

Clinical Care Options (CCO) expert analysis by Prof Stefan Zeuzem on new viral hepatitis data from EASL 2022, including HBV, HDV, and HCV

Stefan Zeuzem, MD Released: July 6, 2022

Clinical Care Options (CCO) podcast with Prof Stefan Zeuzem on key viral hepatitis data from EASL 2022, including HBV, HDV (hepatitis delta), and HCV

Stefan Zeuzem, MD Released: July 6, 2022

Clinical Care Options (CCO) podcast with Dr Nancy Reau on exciting viral hepatitis data from EASL, including HBV, HDV (hepatitis delta), and HCV

Nancy Reau, MD Released: July 5, 2022

Clinical Care Options (CCO) expert audio: Dr Carla Coffin discusses investigational HBV cure strategies

person default Carla Coffin, MD Released: June 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings